Navegando por Palavras-chave "Parkinson Disease"
Agora exibindo 1 - 4 de 4
Resultados por página
Opções de Ordenação
- ItemAcesso aberto (Open Access)Análise da fluência de fala na Doença de Parkinson(Universidade Federal de São Paulo (UNIFESP), 2011-01-26) Brabo, Natália Casagrande [UNIFESP]; Ortiz, Karin Zazo [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Purpose: to characterize the frequency of occurrence and typology of disfluencies in individuals with PD verifying their relationship with the dysarthria and praxis verbal and nonverbal. Methods: This was a transversal observational study in which were analyzed 60 subjects, over 60 years, paired by their age and gender. The group was composed by 30 normal controls patients and 30 with PD. In order to evaluate the speech fluency, it was requested to the patients to narrate a story based on a picture description with seven pictures and was realized a transcript of 200 fluent syllables for verification of disfluencies and speech rate. So it was able to evaluate the speech praxis by the Boston Diagnosis of Aphasia, a dysarthria protocol. The patient’s performance was compared with the control group. Results: there was no difference between groups regarding gender, age and education. The PDG presented a greater number of total and atypical disfluencies in speech and worst praxis verbal and nonverbal compared to CG. All subjects with PD presented hypokinetic dysarthria. Typical and atypical disfluencies of speech were highly related to the dysarthria frame than to the praxis verbal and non-verbal ones. Conclusion: the atypical disfluencies are present in the speech of PD patients and they are more related to the dysarthria.
- ItemAcesso aberto (Open Access)Análise quantitativa da deglutição de parkinsonianos pré e pós-riboflavina(CEFAC Saúde e Educação, 2014-08-01) Silvério, Carolina Castelli [UNIFESP]; Coimbra, Cicero Galli [UNIFESP]; Chiari, Brasilia Maria [UNIFESP]; Lederman, Henrique Manoel [UNIFESP]; Gonçalves, Maria Inês Rebelo [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)Purposeto verify the quantitative changes in the swallowing dynamics in patients with Parkinson´s disease submitted to treatment with riboflavin, red meat and poultry removed during one year period. Methodsixteen patients with Parkinson´s disease participated in the study; the mean age was 67.25 years, the mean degree of disease severity was II to III, and the mean time since the diagnosis of the disease was 3.5 years. Videofluoroscopic evaluations were performed before and one year after treatment with riboflavin and diet with restriction of read meat and poultry. Analyzed werepresence of complaints related to swallowing and quantitative analyses of swallowing includind computerized measurements of hyoid bone and cricoid cartilage displacement, opening of the superior esophageal sphincter and pharyngeal constriction. Resultdecrease of complaints was observed after administration of riboflavin. About the quantitative measures after riboflavin, there were a increase in the opening of the superior esophageal sphincter for all consistencies offered, an increase in the pharyngeal constriction for the thickened liquid, a reduction in the hyoide bone displacement, and an increase or a reduction in the cricoid cartilage displacement for each consistency, with significant reduction for the liquid. Conclusionquantitative measurements made in the movement of organs associated with swallowing showed no significant differences between pre-and post-riboflavin, and red meat and poultry removed.
- ItemAcesso aberto (Open Access)Estudo da modulação da autofagia pelos compostos canabinoides em modelos de neurodegeneração em Caenorhabditis elegans(Universidade Federal de São Paulo, 2024-11-01) Guedes, Erika da Cruz [UNIFESP]; Pereira, Gustavo José da Silva [UNIFESP]; Reckziegel, Patrícia [UNIFESP]; http://lattes.cnpq.br/7046429718251220; http://lattes.cnpq.br/7125107888186769; http://lattes.cnpq.br/7765105091553486Distúrbios neurodegenerativos progressivos, como a doença de Parkinson (DP), não possuem tratamentos de cura ou de longo prazo. Com o envelhecimento acelerado da população global e o consequente aumento na prevalência de doenças associadas à idade, há um crescente interesse em pesquisas sobre esses distúrbios. Estudos indicam que o processo de autofagia, responsável pela homeostase celular, pode estar comprometido em doenças neurodegenerativas. Neste contexto, investigamos a ação do canabidiol (CBD) como possível agente neuroprotetor na DP usando o modelo de C. elegans exposto à reserpina. Além disso, usamos cepas transgênicas de C. elegans que expressam a α-sinucleína, proteína considerada marcador patológico da DP. Nossos resultados demonstraram que o CBD reverteu as alterações locomotoras induzidas pela reserpina e essa resposta foi independente dos receptores NPR-19 (receptor ortólogo para o receptor canabinoide central tipo 1 de mamíferos). As avaliações morfológicas dos neurônios dopaminérgicos cefálicos (CEPs) indicaram que o CBD também reverteu os danos neuronais induzidos pela reserpina, aumentando o número de vermes com neurônios CEPs intactos. Mecanisticamente, demonstrou-se que o CBD também reduziu o acúmulo de espécies reativas de oxigênio (EROs) e a expressão de α-sinucleína em vermes mutantes, sendo esse efeito provavelmente mediado pela ativação da autofagia via fator de transcrição EB (TFEB). Em conjunto, nossos resultados forneceram evidências de que o CBD pode atuar como neuroprotetor em neurônios dopaminérgicos, reduzindo a neurotoxicidade e o acúmulo de α-sinucleína, destacando seu potencial no tratamento da DP.
- ItemAcesso aberto (Open Access)O receptor P2X7 e a via de PGC-1A/PPAR como alvos na estratégia do desenvolvimento de terapias para a doença de Parkinson(Universidade Federal de São Paulo (UNIFESP), 2017-08-08) Ferrazoli, Enéas Galdini [UNIFESP]; Ulrich, Alexander Henning [UNIFESP]; Gomes, Telma Tiemi Schwindt Diniz [UNIFESP]; http://lattes.cnpq.br/8780348666074054; http://lattes.cnpq.br/9571481236686866; http://lattes.cnpq.br/7508889777108883; Universidade Federal de São Paulo (UNIFESP)Parkinson's Disease (PD) is characterized by the loss of dopaminergic neurons in the substantia nigra and their projections to the striatum, and there are no therapies that significantly delay its progression so far. Currently, the most common treatment for PD is the administration of Levodopa, but this drug has limited efficacy and many side effects, such as dyskinesias. Recently, several groups have demonstrated the participation of purinergic receptors, especially the P2X7 receptor (P2X7R), and the peroxisome proliferator activated receptor (PPAR), in neuroinflammatory and neurodegenerative pathways, suggesting that these might be important targets for therapies for neurodegenerative diseases. It is also known that the inflammation process is closely linked to the mechanisms of neuronal death in PD. Further, neural stem / progenitor cells express various chemokines and chemokine receptors that are involved in the homing of these cells to sites of injury in the central nervous system; thus transplantation of neural stem / progenitor cells is indicated as a promising strategy for the treatment of neurodegenerative diseases. The objective of the present study was to evaluate the therapeutic effect of the use of the P2X7R blocker Brilliant Blue G, the PPAR activator fenofibrate, and neural progenitor cell transplantation in an in vitro model for PD. For this purpose, we used the hemiparkinsonism model induced by 6-hydroxy-dopamine. The apomorphine-induced rotational behavior, characteristic of this model, and histological analysis of tyrosine hydroxylase expression were used as parameters to determine the effects of the used treatments. The obtained results obtained show that the blockade of P2X7R by BBG induced a significant decrease of apomorphine-evoked rotations and the recovery of dopaminergic neurons in the substantia nigra. However, treatments with fenofibrate and neural progenitor cells did not promote any improvement compared to animals treated with saline. In summary, we can conclude that P2X7R may be an important therapeutic target in Parkinson's disease.